Fig. 3
From: Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
The strategy to combine inhibition of purinergic pathway and other antitumor therapies. Several components within purinergic signaling pathway including A2AR, A2BR, CD39 and CD73 can be targeted together to achieve synergy in antitumor efficacy by modulating both tumor cells and immune cells, for example, DC and Teff, by pharmacological antagonist and/or antibodies. In addition, targeting purinergic pathway in combination with other therapies such as ICIs, CT, TT, and RT can also develop potential robust strategies to enhance therapeutic benefit in various cancers, which is currently examined and will be further demonstrated in many important clinical trials. A2AR, A2A adenosine receptor; A2BR, A2B adenosine receptor; ADO, adenosine; ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, adenosine triphosphate; CT, chemotherapy; CTLA4, cytotoxic T-lymphocyte associated protein 4; DC, dendritic cell; ICI, immune checkpoint inhibitor; MHC I, major histocompatibility complex class I; PD1, programmed cell death protein 1; PD-L1, programmed cell death protein ligand 1; RT, radiotherapy; TCR, T-cell receptor; Teff, effector T cell; TT, targeted therapy. Partly created by Figdraw (www.figdraw.com)